Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics

William G. Cance, Elena Kurenova, Timothy Marlowe, Vita Golubovskaya

Research output: Contribution to journalReview articlepeer-review

83 Scopus citations


Focal adhesion kinase (FAK) is emerging as a promising cancer target because it is highly expressed at both the transcriptional and translational level in cancer and is involved in many aspects of tumor growth, invasion, and metastasis. Existing FAK-based therapeutics focus on inhibiting the kinase's catalytic function and not the large scaffold it creates that includes many oncogenic receptor tyrosine kinases and tumor suppressor proteins. Targeting the FAK scaffold is a feasible and promising approach for developing highly specific therapeutics that disrupt FAK signaling pathways in cancer.

Original languageEnglish (US)
Pages (from-to)pe10
JournalScience signaling
Issue number268
StatePublished - Mar 26 2013
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics'. Together they form a unique fingerprint.

Cite this